Pliant Therapeutics, Inc. (PLRX)

Over the past six months, Pliant Therapeutics announced an upcoming presentation of Phase 1 clinical trial data for PLN-101095 in solid tumors at the 2026 AACR Annual Meeting, provided a corporate update and reported its Fourth Quarter 2025 Financial Results, filed a $300M shelf and a $50M at-the-market (ATM) program with Leerink, and shifted to a new $50M ATM program in March 2026. The company participated in the Oppenheimer Healthcare Life Science Conference in February 2026. In December 2025, Pliant Therapeutics announced interim data from PLN-101095, which led to a stock price decrease of 14.94%, and participated in the Piper Sandler Healthcare Conference. In November 2025, Pliant Therapeutics provided a corporate update and reported Third Quarter 2025 Financial Results, with the stock seeing a 4.58% increase.

As a clinical-stage biopharmaceutical company, Pliant Therapeutics, Inc. does not have traditional demand seasonality for its products and services. Its revenue and operations are primarily driven by research and development milestones, clinical trial progress, and potential future regulatory approvals, rather than seasonal consumer demand.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies. Its major product candidates include Bexotegrast (PLN-74809) for IPF and PSC, PLN-101095 for advanced or metastatic solid tumors, PLN-101325 for muscular dystrophies, and PLN-1474 for NASH with liver fibrosis. Development of bexotegrast in IPF within the BEACON-IPF trial was discontinued following a safety and efficacy review.

Pliant Therapeutics, Inc. is headquartered in South San Francisco, California, with some sources mentioning Redwood City, California, as a headquarters location. The company's operations are primarily focused on research and development activities within the United States.

Pliant Therapeutics' brand reputation has been influenced by its clinical trial progress and financial performance. The company has received a consensus rating of "Reduce" or "Hold" from analysts, and its stock has underperformed both the US Pharmaceuticals industry and the broader US market. The discontinuation of the BEACON-IPF trial, interim data for PLN-101095, and a workforce reduction have affected its reputation.

Pliant Therapeutics, Inc. has significant institutional ownership, with 104 institutional owners holding approximately 75.41% of the company's stock as of April 9, 2026. Major institutional owners include Tang Capital Management Llc, Blue Owl Capital Holdings LP, and Vanguard Group Inc. The largest individual shareholder is Matthew G. Robinson, who owns 25.95% of the company. Insider ownership stands at 42.31%.